Market Overview - The A-share market continues to rise, with the Shanghai Composite Index closing at 3534.48 points, marking a new high for the year [1] - The overall performance of ETFs has been active, particularly in the Hong Kong innovative drug sector, which has led the gains [1][2] ETF Performance - Nearly 1100 ETF products saw gains this week, with a median weekly increase of approximately 1.29%, slightly up from the previous week [2] - The top-performing ETFs include several Hong Kong innovative drug-related ETFs, with weekly gains exceeding 13% [4][6] - Notable ETFs include: - 恒生创新药ETF: 13.686% weekly gain, 89.746% year-to-date gain - 港股通创新药ETF: 13.248% weekly gain, 15.631% year-to-date gain - 港股创新药ETF基金: 13.128% weekly gain, 89.775% year-to-date gain [4] Sector Highlights - The Hong Kong innovative drug sector saw significant individual stock performances, with 康方生物 rising nearly 24% and 三生制药 increasing by 23% [6] - The entrepreneurial board's artificial intelligence ETFs also experienced over 10% gains, driven by strong performances from companies like 新易盛 and 中际旭创 [6] Declining Sectors - The gaming ETF sector faced declines, with several products dropping over 3% this week [7][10] - Other underperforming sectors included financial technology, photovoltaic, and real estate ETFs, with the banking ETF also experiencing a decline after reaching historical highs [10]

Market Overview - The Hang Seng Index closed at 24,518, down 0.08% for the day but up 22.13% year-to-date[3] - The Hang Seng China Enterprises Index ended at 8,861, decreasing by 0.09% daily and up 21.44% year-to-date[3] - The Hang Seng Tech Index rose by 0.56% to 5,418, with a year-to-date increase of 21.95%[3] Sector Performance - Biopharmaceutical stocks surged, with Kanghua rising 14.5% and other companies like Kangfang Bio and Baiji Shenzhou increasing over 10%[9] - Major tech stocks showed mixed results, with Meituan up over 1% while Baidu fell over 3%[9] - Li Auto's stock increased by over 9% following the announcement of pre-orders for its new model priced between 350,000 to 400,000 RMB[9] U.S. Market Highlights - The Nasdaq Composite rose by 0.74%, the S&P 500 increased by 0.54%, and the Dow Jones Industrial Average gained 0.52%, all reaching new closing highs[9] - Nvidia's stock rose by 0.95%, while Microsoft increased by 1.20%, both achieving historical closing highs[9] - Netflix reported a net profit of $3.125 billion for Q2 2025, a 45.6% year-on-year increase, and raised its revenue and profit margin guidance for the year[9] Economic Indicators - U.S. retail sales rose by 0.6% in June, exceeding expectations, primarily driven by a rebound in auto sales[12] - The U.S. unemployment claims fell to 221,000, indicating a resilient job market despite a slowdown in hiring[12] - U.S. tariff revenues surged to $87.2 billion in the first half of the year, with June alone accounting for $26.6 billion, four times the usual level[12]

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

Fund Issuance and Performance - The issuance of new funds has reached record levels this year, with the Dachen Insight Advantage Mixed Fund raising 2.46 billion yuan, setting a new high for active equity fund launches in 2023. This follows the Huashang Zhi Yuan Return Mixed Fund, which raised 2.082 billion yuan just a day earlier. The total issuance of active equity funds has increased by 28.01% year-on-year [1][2] - A total of 50 active equity funds have been liquidated this year, with 6 funds entering liquidation procedures in July alone [3] ETF Market Dynamics - The first batch of Sci-Tech Bond ETFs has seen significant inflows, with the Huaxia Sci-Tech Bond ETF surpassing 14.2 billion yuan in size, reflecting a daily increase of over 378%. Additionally, the Penghua Sci-Tech Bond ETF has also exceeded 10.9 billion yuan [2] - The overall market showed mixed performance, with the Shanghai Composite Index rising by 0.5%, the Shenzhen Component Index by 0.37%, and the ChiNext Index by 0.34%. The total trading volume in the two markets reached 1.57 trillion yuan, an increase of 31.7 billion yuan from the previous trading day [5] Notable Fund Manager Activities - Gao Nan, Chief Equity Investment Officer at Yongying Fund, has concentrated his portfolio in TMT and innovative pharmaceutical sectors. His flagship fund, Yongying Ruixin, includes top holdings such as Pop Mart, Zhongji Xuchuang, and Kangfang Biotech, with several stocks being newly added or increased in weight [4] Sector Performance Insights - The rare earth permanent magnet sector has shown strong performance, with stocks like Huahong Technology hitting the daily limit. The rare metal ETFs led the market with a gain of 4.12% [5][7] - The gaming market is in an upward cycle, with expectations for long-term growth in revenue and player numbers. The introduction of advanced generative capabilities in game development is anticipated to enhance efficiency and user engagement [8]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 0.56% on July 18, with a trading volume of 2.25 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of July 17, 2024, the fund's latest share count was 2.025 billion, with a total size of 3.63 billion yuan, reflecting an increase of 412.28% in shares and 860.92% in size since December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 79.25% during the management period [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's trading liquidity is strong, with a cumulative trading amount of 40.368 billion yuan over the last 20 trading days, averaging 2.018 billion yuan per day [1][2]

Group 1: Market Overview - The report indicates that concerns over economic recession have eased, with US stock markets reaching new highs, suggesting that Hong Kong stocks may follow suit [2][4] - The Hang Seng Index showed slight fluctuations, closing at 24,498 points, down 18 points or 0.08%, with trading volume decreasing to 236.4 billion HKD, an 8.7% drop from the previous day [2][3] - Northbound trading maintained a net inflow status, with a net inflow of 1.855 billion HKD, an increase of 15.7% from the previous day [2] Group 2: Sector Performance - Among the 12 Hang Seng Composite Industry Indices, 6 rose and 6 fell, with the healthcare sector leading with a significant increase of 5.17% [3] - Other sectors that performed well included consumer staples and industrials, with gains ranging from 0.67% to 0.21% [3] - The materials, energy, and financial sectors experienced declines, with losses between 1.00% and 0.31% [3] Group 3: Company Analysis - Derlin International (1126.HK) - Derlin International is a leading global toy manufacturer, established in 1992 and listed in Hong Kong in 2002, focusing on designing, developing, producing, and selling toys [6] - The company reported revenues of 27.66 billion HKD from plush toys (50.7% of total revenue) and 23.11 billion HKD from plastic models (42.4% of total revenue) for 2024 [6][8] - Derlin operates 27 factories with an average capacity utilization rate of 80.2% in 2024, with plans for further capacity expansion in Indonesia and Vietnam to meet diverse supply chain demands [7][9] Group 4: Financial Performance - Derlin's revenue over the past three years showed fluctuations: 62.53 billion HKD in 2022, 53.52 billion HKD in 2023, and 54.50 billion HKD in 2024, with a year-on-year growth of 30.27%, -14.40%, and 1.82% respectively [8] - The gross profit margins were 19.65%, 25.12%, and 23.01% for the same years, influenced by product mix changes [8] - The net profit figures were 6.87 billion HKD, 8.30 billion HKD, and 7.38 billion HKD, reflecting a growth of 255%, 20.78%, and a decline of 11.01% respectively [8] Group 5: Future Outlook - Derlin International is positioned to benefit from the trend of popular toys, supported by a strong design and R&D team, with four design centers and approximately 150 designers [9] - The company’s ownership of factories in China and Vietnam provides a competitive edge in the context of supply chain diversification [9] - The report anticipates that as the demand for trendy toys increases, Derlin will continue to expand its capacity and seize more business opportunities [9]

Core Viewpoint - The AI Fund, Rongtong Xinxin Growth Mixed A, reported a profit of 35.4486 million yuan for Q2 2025, with a net value growth rate of 12.82% and a fund size of 400 million yuan as of the end of Q2 2025 [2][15]. Fund Performance - As of July 17, 2025, the fund's one-year cumulative net value growth rate was 48.74%, ranking 50 out of 133 comparable funds [3]. - The fund's three-month net value growth rate was 21.94%, ranking 84 out of 138 comparable funds, while the six-month growth rate was 29.74%, ranking 86 out of 138 [3]. - The fund's three-year Sharpe ratio was 0.4914, ranking 12 out of 105 comparable funds [8]. Investment Strategy - The fund adheres to a contrarian investment style, focusing on sectors and stocks with good growth potential and relatively low valuations, while adjusting the portfolio structure as needed [2]. - The investment direction emphasizes domestic demand and technology, with a focus on opportunities arising from China's economic transformation and recovery [2]. - The fund is optimistic about investment opportunities in the pharmaceutical sector, particularly in the context of aging demographics, as well as in innovative drugs and high-end manufacturing with global competitive advantages [2]. Portfolio Composition - As of June 30, 2025, the fund's average stock position over the past three years was 92.67%, with a peak of 94.34% at the end of H1 2025 [13]. - The top ten holdings of the fund include companies such as Aibo Medical, Gushengtang, and Sanyou Medical, indicating a strong focus on the healthcare sector [18]. Risk Metrics - The fund's maximum drawdown over the past three years was 38.36%, ranking 59 out of 105 comparable funds, with the largest single-quarter drawdown occurring in Q1 2024 at 27.81% [10].

Group 1 - Nomura predicts that Kangfang Biotech (09926.HK) will turn from loss to profit in the second half of the year, raising the target price to HKD 120.64 [1] - The company’s mid-term revenue is expected to increase by 42% year-on-year to RMB 1.45 billion, which is 3% lower than market expectations [1] - Sales of the drugs Oritavancin and Ibrutinib are anticipated to accelerate, contributing RMB 800 million and RMB 600 million to mid-term revenue respectively [1] Group 2 - Mid-term operating expenses are projected to be RMB 1.3 billion, with an expected overall mid-term loss attributable to shareholders of RMB 8 million, nearing breakeven [1] - In comparison, the company recorded losses of RMB 239 million and RMB 276 million in the first and second halves of the previous year [1] - For the second half of the year, revenue is forecasted to reach RMB 1.9 billion, driven by sales of Oritavancin and Ibrutinib, with a projected net profit of RMB 271 million [1] Group 3 - The company has adjusted its revenue forecast for the year down by 9.6%, based on lowered expectations for sales and collaboration income from Anika [1] - However, the annual net profit forecast has been raised by 97.2%, based on higher gross margin assumptions [1] - The target price for Kangfang Biotech has been increased from HKD 99.66 to HKD 120.64, while maintaining a neutral rating [1]

AI基金国投瑞银创新医疗混合A（005520）披露2025年二季报，第二季度基金利润461.85万元，加权平均基金份额本期利润0.0779元。报告期内，基金净值 增长率为9.05%，截至二季度末，基金规模为5513.18万元。 该基金属于灵活配置型基金，长期投资于医药医疗股票。截至7月17日，单位净值为1.08元。基金经理是刘泽序，目前管理2只基金近一年均为正收益。其 中，截至7月17日，国投瑞银创新医疗混合A近一年复权单位净值增长率最高，达41.33%；国投瑞银医疗保健混合A最低，为31.01%。 基金管理人在二季报中表示，投资方向上，我们继续加仓了创新药板块，尤其是基本面和估值匹配度较高的港股创新药，并看重创新药企业的估值和确定 性。选股方向上，我们主要关注以下企业：已经落地BD、等待临床兑现的企业；BD概率较高的企业；估值中对BD预期不高的企业。同时，非创新药板块 我们认为依然值得重视，并保持了一定仓位的布局，如科研服务、CXO、医疗器械等。 截至7月17日，国投瑞银创新医疗混合A近三个月复权单位净值增长率为25.54%，位于同类可比基金67/138；近半年复权单位净值增长率为43.45%，位于同 类可 ...

Core Insights - The report highlights the significant growth potential in the measurement and calibration industry, driven by new policies aimed at enhancing manufacturing capabilities in China [6][7][8] - The renewable energy sector, particularly in electric power equipment, is poised for growth due to supportive policies in the UK and increasing demand for energy storage solutions [13] - The pharmaceutical industry is recommended for investment, focusing on innovative drugs and their supply chains, with strong support from health insurance reforms [14] Industry and Company Analysis - **Measurement and Calibration Industry**: The first policy document from the Ministry of Industry and Information Technology emphasizes the need for precise measurement to drive innovation in manufacturing. This includes establishing a service network and digital transformation paths, with a focus on high-level calibration institutions and digital measurement software [6][7] - **Renewable Energy Sector**: The UK government has restarted subsidies for electric vehicles and charging infrastructure, indicating a robust market for energy storage systems. The report suggests focusing on companies involved in battery production and charging infrastructure, such as Ningde Times and Keda Technology [13] - **Pharmaceutical Industry**: The report continues to recommend innovative drug sectors, highlighting the recent adjustments in health insurance and commercial insurance that favor high-value innovative drugs. Companies like Kelun-Biotech and Innovent Biologics are noted for their strong potential in both domestic and international markets [14] - **Oil and Gas Sector**: China National Offshore Oil Corporation (CNOOC) has made significant advancements in oil and gas exploration, achieving record production levels in both domestic and international operations. The report anticipates continued growth in production capacity, particularly in the Stabroek block in Guyana [20][21][24]